This enhanced RAC2-PLCγ2 interaction was also observed in chronic lymphocytic leukemia cells from patients with treatment-resistant or progressive disease on BTK inhibitor treatment [94]. Here, RAC2 is linked to B-cell chronic lymphocytic leukemia.